Måndag 23 December | 19:00:45 Europe / Stockholm

Prenumeration

Kalender

Tid*
2026-02-12 N/A Bokslutskommuniké 2025
2025-11-11 N/A Kvartalsrapport 2025-Q3
2025-08-12 N/A Kvartalsrapport 2025-Q2
2025-05-08 N/A Årsstämma
2025-05-08 N/A Kvartalsrapport 2025-Q1
2025-02-20 N/A Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning VIVE 0.00 SEK
2024-05-23 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning VIVE 0.00 SEK
2023-05-25 - Årsstämma
2023-05-25 - Kvartalsrapport 2023-Q1
2023-02-23 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning VIVE 0.00 SEK
2022-05-25 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-17 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning VIVE 0.00 SEK
2021-05-25 - Kvartalsrapport 2021-Q1
2020-09-10 - X-dag ordinarie utdelning VIVE 0.00 SEK
2020-09-09 - Årsstämma
2020-06-18 - Bokslutskommuniké 2020
2020-05-14 - Extra Bolagsstämma 2020
2020-03-27 - Kvartalsrapport 2020-Q3
2019-12-30 - Kvartalsrapport 2020-Q2
2019-11-06 - Extra Bolagsstämma 2019
2019-09-27 - X-dag ordinarie utdelning VIVE 0.00 SEK
2019-09-26 - Årsstämma
2019-09-26 - Kvartalsrapport 2020-Q1
2019-07-12 - Bokslutskommuniké 2019
2019-03-01 - Kvartalsrapport 2019-Q3
2018-11-30 - Kvartalsrapport 2019-Q2
2018-09-25 - Årsstämma
2018-09-05 - X-dag ordinarie utdelning VIVE 0.00 SEK
2018-08-31 - Kvartalsrapport 2019-Q1
2018-06-08 - Bokslutskommuniké 2018
2018-03-02 - Kvartalsrapport 2018-Q3
2017-12-01 - Kvartalsrapport 2018-Q2
2017-09-26 - X-dag ordinarie utdelning VIVE 0.00 SEK
2017-09-25 - Årsstämma
2017-09-01 - Kvartalsrapport 2018-Q1
2017-06-08 - Bokslutskommuniké 2017
2017-03-03 - Kvartalsrapport 2017-Q3
2016-12-02 - Kvartalsrapport 2017-Q2
2016-11-21 - Extra Bolagsstämma 2016
2016-09-27 - X-dag ordinarie utdelning VIVE 0.00 SEK
2016-09-26 - Årsstämma
2016-09-02 - Kvartalsrapport 2017-Q1
2016-06-03 - Bokslutskommuniké 2016
2016-03-03 - Kvartalsrapport 2016-Q3
2015-12-03 - Kvartalsrapport 2016-Q2
2015-09-29 - X-dag ordinarie utdelning VIVE 0.00 SEK
2015-09-28 - Årsstämma
2015-09-03 - Kvartalsrapport 2016-Q1
2015-06-04 - Bokslutskommuniké 2015
2015-03-05 - Kvartalsrapport 2015-Q3
2014-12-04 - Kvartalsrapport 2015-Q2
2014-09-30 - X-dag ordinarie utdelning
2014-09-29 - Årsstämma
2014-09-05 - Kvartalsrapport 2015-Q1
2014-06-05 - Bokslutskommuniké 2014
2014-03-06 - Kvartalsrapport 2014-Q3
2013-12-05 - Kvartalsrapport 2014-Q2
2013-10-01 - X-dag ordinarie utdelning VIVE 0.00 SEK
2013-09-06 - Kvartalsrapport 2014-Q1
2013-06-07 - Bokslutskommuniké 2013
2013-03-13 - 15-7 2013
2013-03-01 - Kvartalsrapport 2012-Q3
2012-12-06 - Kvartalsrapport 2012-Q2
2012-09-25 - X-dag ordinarie utdelning VIVE 0.00 SEK
2012-09-24 - Årsstämma
2012-09-06 - Kvartalsrapport 2012-Q1
2012-06-14 - Bokslutskommuniké 2011
2012-03-08 - Kvartalsrapport 2011-Q3
2011-12-08 - Kvartalsrapport 2011-Q2
2011-10-03 - X-dag ordinarie utdelning VIVE 0.00 SEK
2011-09-30 - Årsstämma
2011-09-08 - Kvartalsrapport 2011-Q1
2011-06-10 - Bokslutskommuniké 2010
2010-12-09 - Kvartalsrapport 2010-Q2
2010-09-24 - Årsstämma
2010-09-09 - Kvartalsrapport 2010-Q1
2009-12-10 - Kvartalsrapport 2009-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Vivesto är ett forskningsbolag. Bolaget är specialiserat inom forskning och utveckling av läkemedel för svåra sjukdomar inom onkologi. Tekniken baseras på bolagets tekniska plattform där forskning sker utifrån nanoteknik. Idag innehas verksamhet främst inom Norden och Nordamerika. Bolaget grundades under 1999 och har idag sitt huvudkontor i Uppsala.
2023-06-16 08:00:00

Solna, June 16, 2023 - Vivesto AB, an oncology-focused research and development company, today announced that the company had a successful and encouraging pre-submission conference (PSC) with the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) regarding development of Paccal Vet.

Vivesto requested the meeting to get the FDA’s feedback on the planned clinical development program for the company’s veterinary oncology drug candidate Paccal Vet (paclitaxel micellar) with the intention to pursue full approval in the US. On a high level, the FDA agreed to Vivesto’s development strategies. The strategy is to perform a pilot study, to evaluate Paccal Vet in dogs with hemangiosarcoma and malignant melanoma, which is to be followed by a pivotal study. Vivesto plans to start the pilot study in the second half of 2023.

“We are encouraged by this successful pre-submission meeting with the FDA regarding Paccal Vet,” said Erik Kinnman, CEO of Vivesto. “There are millions of dogs in the US and EU developing cancer each year and few approved drugs for treatment. Our plan to start clinical development of Paccal Vet is a critical first step to advancing this drug and expanding treatment options in this rapidly growing market.”

The company received advice on major technical sections Chemistry Manufacturing and Controls (CMC), Target Animal Safety (TAS), Environmental Impact (EI) and Effectiveness. Vivesto also received advice regarding MUMS (Minor Use/Minor Species) application and designation.

About hemangiosarcoma in dogs
Hemangiosarcoma is one of the most common malignant cancers in dogs and is associated with a poor prognosis, with less than 10% of dogs surviving 12 months. The number of dogs diagnosed with hemangiosarcoma annually in the US and Europe is approximately 75,000 per market. Dogs with hemangiosarcoma rarely show clinical symptoms until the tumor has grown very large and spread. Treatment options for hemangiosarcoma include surgery and adjuvant chemotherapy.

About malignant melanoma in dogs
The number of dogs diagnosed with malignant melanoma annually in the US and Europe is approximately 60,000 per market. The most common primary site is the oral cavity (80%), with a median survival time of 65 days (oral cancer) in dogs left untreated. Malignant melanomas are highly proliferative, spreading primarily to local lymph nodes and lungs. Surgery and/or radiotherapy are the main treatment options today and target local disease, therefore metastatic disease is still the main cause of death for dogs with malignant melanoma. Consequently, chemotherapy is also considered for the treatment of metastatic and non-operable melanoma. Between 20-30% respond to currently available treatment.


For More Information: 
Erik Kinnman, Chief Executive Officer at Vivesto
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com

About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a portfolio of projects with the potential of offering cancer patients with unmet medical needs new treatment alternatives. Vivesto has a track-record of developing drugs from the preclinical stage, through clinical development to regulatory approval. Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. Other clinical development programs include Cantrixil for late-stage ovarian cancer, and Docetaxel micellar, in development for advanced prostate cancer. Vivesto has developed proprietary drug delivery technologies designed to improve solubility of various active pharmaceutical ingredients.

Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.